Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$486.55 USD

486.55
1,155,146

-3.88 (-0.79%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $486.29 -0.26 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Align Technology at 52-Week High: What's Driving the Stock?

Align Technology (ALGN) consistently invests in R&D for product innovation.

    Myriad Genetics (MYGN) Beats on Q1 Earnings & Revenues

    Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, Hereditary cancer tests continue to witness year-over-year volume growth.

      Inogen (INGN) Beats Earnings and Revenue Estimates in Q3

      Inogen's (INGN) stellar third-quarter numbers benefit from direct-to-consumer sales and lower cost of goods sold per unit.

        Phibro Animal (PAHC) Beats on Q1 Earnings, Reiterates View

        Phibro Animal (PAHC) witnesses year-over-year improvement across all segments in Q1.

          Wright Medical (WMGI) Portfolio Solid, Lower Extremities Dull

          Wright Medical (WMGI) is focusing on product innovation through research and development. However, lackluster international performance of the Lower extremities segment is a matter of concern.

            QIAGEN (QGEN) Meets Q3 Earnings, Lags Revenues, Keeps View

            QIAGEN's (QGEN) top line gains from strength in the Molecular Diagnostics space in Q3.

              Hill-Rom (HRC) Q4 Earnings and Revenues Top, Margins Up

              Hill-Rom (HRC) witnesses strong revenue growth in Q4, driven by a solid momentum in core business, acquisition of Mortara and contribution from product launches.

                CVS Health (CVS) Beats Q3 Earnings Estimates, Updates View

                CVS Health (CVS) witnesses year-over-year growth in revenues on the back of strength in the Pharmacy Services segment in Q3.

                  Henry Schein (HSIC) Misses Q3 Earnings, Margins Decline

                  Henry Schein (HSIC) maintains stellar top-line performance in Q3, courtesy of strength in all business segments.

                    CONMED (CNMD) Q3 Earnings and Revenues Beat, Margin Down

                    CONMED (CNMD) gains from strength in General Surgery business in Q3, driven by strong performances by Advanced Surgical and Endoscopic Technologies.

                      Cardinal Health (CAH) Beats on Q1 Earnings, FY18 View Intact

                      Solid growth at Medical Segment drove Cardinal Health's (CAH) first-quarter results. Product launches and completion of strategic acquisitions in the quarter are major positives.

                        BioScrip (BIOS) Q3 Loss Wider Than Expected, Revenues Miss

                        BioSrip (BIOS) Q3 revenues affected by the company's shift in strategy to focus on core revenue mix, the impact of the Cures Act and contract modifications with UnitedHealthcare.

                          Bruker (BRKR) Q3 Earnings & Revenues Beat Estimates, View Up

                          Bruker (BRKR) raises 2017 guidance. The year-over-year increase in Q3 revenues encourages.

                            Allscripts (MDRX) Q3 Earnings Meet, Revenues Beat Estimates

                            Allscripts' (MDRX) solid guidance for 2017 and a bullish long-term outlook are key highlights of Q3. The expansion in margins is encouraging.

                              PerkinElmer (PKI) Beats Q3 Earnings, Updates '17 Guidance

                              PerkinElmer (PKI) posted stellar third-quarter numbers from strong performance in particularly the Diagnostics segment.

                                Pacific Biosciences (PACB) Q3 Loss Narrower Than Estimated

                                Pacific Biosciences (PACB) witnesses solid contribution from the Instrument and Consumable revenue platforms. Consumable revenue growth was driven by higher installed base of instruments.

                                  DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q3

                                  DENTSPLY SIRONA (XRAY) reported third-quarter 2017 adjusted earnings per share (EPS) of 70 cents, beating the Zacks Consensus Estimate by 4 cents.

                                    Align Technology (ALGN) Gains on InvisAlign, Competition Rife

                                    Align Technology (ALGN) continues to gain from strength in the InvisAlign space.

                                      DexCom (DXCM) Q3 Loss Narrower Than Expected, Revenues Meet

                                      DexCom (DXCM) rides high on Sensor and Transmitter revenues in Q3.

                                        Omnicell's Higher Investments Drive Costs, Competition Rife

                                        Omnicell (OMCL) continues to battle escalating costs emanating from several strategies adopted by the company. A tough competitive landscape also acts as a dampener.

                                          STERIS (STE) Q2 Earnings Miss & Revenues Beat, Margins Up

                                          STERIS (STE) witnessed year-over-year decline in Q2 revenues due to softness in Healthcare Products and the Healthcare Specialty Services segments.

                                            Integra Gains on Global Growth, Hurricanes Hamper Business

                                            Integra (IART) launches new regenerative products within its Orthopedics and Tissue Technologies segment. However, hurricanes in Q3 grossly affect the wound care and orthopedic procedures in Florida.

                                              Becton, Dickinson (BDX) Beats on Q4 Earnings, Guidance Solid

                                              Becton, Dickinson's (BDX) guidance for fiscal 2018 buoys optimism for investors. The company's Life Sciences business will be a key growth driver.

                                                Wright Medical Group (WMGI) Q3 Earnings In Line, Sales Miss

                                                Wright Medical (WMGI) posted loss as estimated in the third quarter on lower-than-expected sales.

                                                  Zimmer Biomet's (ZBH) Q3 Earnings Lag Estimates, View Down

                                                  Zimmer Biomet's (ZBH) declining revenue performance within most of the core segments, along with a rise in cost of products sold resulted in bottom line pressure in the third quarter.